NEW YORK (GenomeWeb News) – Genetic testing service firm 23andMe has done away with its subscription model following pushback from its customers and genetic genealogists.

In a note to its subscribers on Tuesday 23andMe CEO Anne Wojcicki said, "We listened to your feedback and now understand that subscriptions were not good for you and thus not good for 23andMe."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.